Company: BWAY
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001171843-25-002347
Chunk: 90

Company: Brainsway Ltd.
Filing Date: 2025-04-22
Form: 20-F
Item: Item 5
Chunk 90
---
 cash equivalents, including the proceeds from the private placement of ADSs and warrants that closed on November
5, 2024, and from our ongoing sales and leases of our Deep TMS systems. For the near future, our investments will mainly remain in the
United States and Israel, where our operations and research and development facilities are currently located.

  Business Overview  

BrainsWay is a global leader in advanced noninvasive
neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial
Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. We are dedicated to leading through
superior science and building on what we believe to be an unparalleled body of clinical evidence. We are the first and only TMS company
to be cleared by the U. S. Food and Drug Administration (FDA) for three separate mental health disorder indications based on clinically
proven efficacy as demonstrated in pivotal randomized placebo-controlled studies. Current indications include major depressive disorder
(MDD) (including reduction of comorbid anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder (OCD),
and smoking addiction.

We have also received CE Mark for a variety of psychiatric
and neurological indications. We are focused on increasing global awareness of and broad access to Deep TMS. Deep TMS uses magnetic pulses
to stimulate neurons and consequently modulates the physiological activity of the brain. Our technology can either increase brain activity
in neuronal networks which are hypoactive, or alternatively decrease brain activity in neuronal networks which are hyperactive. Our proprietary
electromagnetic coils, which we refer to as H-Coils, are designed to safely stimulate deep and broad brain regions, which we believe provides
an advantage over other available TMS products, which we refer to collectively as Traditional TMS, that generally use a “figure
8” design. In the United States, we sell our Deep TMS system for the treatment of MDD (including reduction of comorbid anxiety symptoms,
commonly referred to as anxious depression) and OCD and have also been marketing our products for the treatment of smoking addictions
since 2023. We believe that our Deep TMS technology has the potential to be safe and effective for the treatment of a wide range of additional
psychiatric, neurological, and addiction disorders. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction
disorders are underway or planned.

  51  

MDD is a common